Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

Patricia L. Earl, Jeffrey L. Americo, Linda S. Wyatt, Leigh Anne Eller, J. Charles Whitbeck, Gary H. Cohen, Roselyn J. Eisenberg, Christopher J. Hartmann, David L. Jackson, David A. Kulesh, Mark J. Martinez, David M. Miller, Eric M. Mucker, Joshua D. Shamblin, Susan H. Zwiers, John W. Huggins, Peter B. Jahrling and Bernard Moss ()
Additional contact information
Patricia L. Earl: National Institutes of Health
Jeffrey L. Americo: National Institutes of Health
Linda S. Wyatt: National Institutes of Health
Leigh Anne Eller: Henry M. Jackson Foundation
J. Charles Whitbeck: University of Pennsylvania
Gary H. Cohen: University of Pennsylvania
Roselyn J. Eisenberg: University of Pennsylvania
Christopher J. Hartmann: United States Army Medical Research Institute of Infectious Diseases
David L. Jackson: United States Army Medical Research Institute of Infectious Diseases
David A. Kulesh: United States Army Medical Research Institute of Infectious Diseases
Mark J. Martinez: United States Army Medical Research Institute of Infectious Diseases
David M. Miller: United States Army Medical Research Institute of Infectious Diseases
Eric M. Mucker: United States Army Medical Research Institute of Infectious Diseases
Joshua D. Shamblin: United States Army Medical Research Institute of Infectious Diseases
Susan H. Zwiers: United States Army Medical Research Institute of Infectious Diseases
John W. Huggins: United States Army Medical Research Institute of Infectious Diseases
Peter B. Jahrling: United States Army Medical Research Institute of Infectious Diseases
Bernard Moss: National Institutes of Health

Nature, 2004, vol. 428, issue 6979, 182-185

Abstract: Abstract The potential use of smallpox as a biological weapon has led to the production and stockpiling of smallpox vaccine and the immunization of some healthcare workers. Another public health goal is the licensing of a safer vaccine that could benefit the millions of people advised not to take the current one because they or their contacts have increased susceptibility to severe vaccine side effects1. As vaccines can no longer be tested for their ability to prevent smallpox, licensing will necessarily include comparative immunogenicity and protection studies in non-human primates. Here we compare the highly attenuated modified vaccinia virus Ankara (MVA)2 with the licensed Dryvax vaccine in a monkey model. After two doses of MVA or one dose of MVA followed by Dryvax, antibody binding and neutralizing titres and T-cell responses were equivalent or higher than those induced by Dryvax alone. After challenge with monkeypox virus, unimmunized animals developed more than 500 pustular skin lesions and became gravely ill or died, whereas vaccinated animals were healthy and asymptomatic, except for a small number of transient skin lesions in animals immunized only with MVA.

Date: 2004
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/nature02331 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:428:y:2004:i:6979:d:10.1038_nature02331

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature02331

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().